← All filing news
listing_deficiencyCYAB

Cyabra receives Nasdaq deficiency notices for minimum bid price and market value

Cyabra received notices on June 9, 2026 from Nasdaq indicating non-compliance with two listing rules: failure to maintain a minimum Market Value of Publicly Held Shares of $15,000,000 and failure to maintain a minimum bid price of $1.00 per share, each measured over the 30 consecutive business days ended June 8, 2026. The company has a 180-calendar-day compliance period ending December 7, 2026 to regain compliance with each rule; if the MVPHS closes at $15,000,000 or more for ten consecutive business days, or the bid price reaches $1.00 or above for ten consecutive business days during the period, the respective deficiency will be cured. If the company fails to regain compliance with the bid price rule by December 7, 2026, it may be eligible for a second 180-calendar-day compliance period, provided it meets other initial listing standards. The stock continues to trade on Nasdaq under symbol CYAB.

CYABRA, INC. · CIK 2032341 ·

Key facts

  • Minimum Market Value of Publicly Held Shares requirement: $15,000,000
  • Minimum bid price requirement: $1.00 per share
  • Measurement period: 30 consecutive business days ended June 8, 2026
  • First compliance period: 180 calendar days from June 9, 2026, expiring December 7, 2026
  • Cure threshold for MVPHS Rule: $15,000,000 or more for 10 consecutive business days
  • Cure threshold for Minimum Bid Rule: $1.00 per share for 10 consecutive business days
  • Nasdaq Listing Rule 5450(b)(2)(C) violated (MVPHS Rule)
  • Nasdaq Listing Rule 5450(a)(1) violated (Minimum Bid Rule)
  • Second compliance period eligible for Minimum Bid Rule deficiency only, if other standards maintained
  • Company may apply to transfer to Nasdaq Capital Market if continued listing requirements are met

Why it matters

Cyabra faces a 180-day window to restore its Nasdaq listing compliance or risk delisting, which would affect the stock's exchange trading status and potential investor access; failure to cure within the prescribed period could result in transfer to a lower-tier market or removal from Nasdaq entirely.

Developing story

  • SCHEDULE 13D
  • SCHEDULE 13D
  • SCHEDULE 13D
  • 8-Kthis filing

Share

Track CYABRA, INC. →

Get the next chapter in your inbox — a Sentinel watches this company and briefs the next material filing the moment it lands.

Derived from 8-K filed 2026-06-12. Not investment advice. View the source filing on SEC.gov →